| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
BCR-ABL, which is a highly activated oncogenic fusion tyrosine kinase in chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ ALL). Although it is well known that tyrosine phosphorylation is important for signal transduction in cytoplasm, roles of nuclear tyrosine phosphorylation in nuclear events is poorly understood. We generated a new BCR-ABL knock-in mice model, and we mated mice with conditional KAP1 knockout mice. Using these mice model, we analyzed the function of tyrosine phosphorylation of KAP1 in normal hematopoiesis and leukemogenesis. Analysis for moceluclar mechanism of tyrosine phosphorylation of KAP1 was performed in K562 CML cell line.
|
